JP2018526986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526986A5 JP2018526986A5 JP2018504815A JP2018504815A JP2018526986A5 JP 2018526986 A5 JP2018526986 A5 JP 2018526986A5 JP 2018504815 A JP2018504815 A JP 2018504815A JP 2018504815 A JP2018504815 A JP 2018504815A JP 2018526986 A5 JP2018526986 A5 JP 2018526986A5
- Authority
- JP
- Japan
- Prior art keywords
- rna complex
- antisense strand
- sequence
- sense strand
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 118
- 230000000692 anti-sense effect Effects 0.000 claims description 49
- 108091081021 Sense strand Proteins 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 108091028664 Ribonucleotide Proteins 0.000 claims description 16
- 239000002336 ribonucleotide Substances 0.000 claims description 16
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 16
- 230000008099 melanin synthesis Effects 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 239000007854 depigmenting agent Substances 0.000 claims description 10
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 10
- 210000002752 melanocyte Anatomy 0.000 claims description 10
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 10
- 239000002777 nucleoside Substances 0.000 claims description 10
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 10
- 210000003491 skin Anatomy 0.000 claims description 10
- 208000031019 skin pigmentation disease Diseases 0.000 claims description 10
- 125000003835 nucleoside group Chemical group 0.000 claims description 7
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N 1,4-Benzenediol Natural products OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 6
- 102000003425 Tyrosinase Human genes 0.000 claims description 6
- 108060008724 Tyrosinase Proteins 0.000 claims description 6
- 208000003351 Melanosis Diseases 0.000 claims description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 5
- 229960000271 arbutin Drugs 0.000 claims description 5
- 229960002255 azelaic acid Drugs 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 229960004337 hydroquinone Drugs 0.000 claims description 5
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 claims description 5
- 229960004705 kojic acid Drugs 0.000 claims description 5
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 claims description 5
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 claims description 5
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 5
- 229960000401 tranexamic acid Drugs 0.000 claims description 5
- 229960001727 tretinoin Drugs 0.000 claims description 5
- 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 3
- 238000007385 chemical modification Methods 0.000 claims description 3
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 239000012466 permeate Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 9
- 238000000338 in vitro Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000026279 RNA modification Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562197370P | 2015-07-27 | 2015-07-27 | |
| US62/197,370 | 2015-07-27 | ||
| PCT/IB2016/001169 WO2017017523A1 (en) | 2015-07-27 | 2016-07-26 | Rna complexes that inhibit melanin production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526986A JP2018526986A (ja) | 2018-09-20 |
| JP2018526986A5 true JP2018526986A5 (enExample) | 2019-09-05 |
| JP7027303B2 JP7027303B2 (ja) | 2022-03-01 |
Family
ID=57885325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504815A Active JP7027303B2 (ja) | 2015-07-27 | 2016-07-26 | メラニン産生を抑制するｒｎａ複合体 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10064801B2 (enExample) |
| JP (1) | JP7027303B2 (enExample) |
| KR (1) | KR102772402B1 (enExample) |
| CN (1) | CN108138181B (enExample) |
| CA (1) | CA3022872C (enExample) |
| WO (1) | WO2017017523A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100949791B1 (ko) * | 2007-12-18 | 2010-03-30 | 이동기 | 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도 |
| ES2930555T3 (es) | 2010-10-22 | 2022-12-16 | Olix Pharmaceuticals Inc | Moléculas de ácido nucleico que inducen la interferencia de ARN y usos de las mismas |
| EP3514236A1 (en) | 2012-05-22 | 2019-07-24 | Olix Pharmaceuticals, Inc. | Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
| US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
| CN108699556B (zh) | 2015-11-16 | 2023-02-17 | 奥利克斯医药有限公司 | 使用靶向myd88或tlr3的rna复合物治疗老年性黄斑变性 |
| CN108779464B (zh) | 2016-02-02 | 2022-05-17 | 奥利克斯医药有限公司 | 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病 |
| KR102825946B1 (ko) | 2016-02-02 | 2025-06-27 | 올릭스 주식회사 | IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료 |
| US10301628B2 (en) | 2016-04-11 | 2019-05-28 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| KR20190108167A (ko) | 2017-02-10 | 2019-09-23 | 성균관대학교산학협력단 | Rna 간섭을 위한 긴 이중가닥 rna |
| US10255780B1 (en) * | 2018-05-29 | 2019-04-09 | David Wittenberg | System and method for detecting and mapping progression of a fire event |
| CN112430597A (zh) * | 2020-11-24 | 2021-03-02 | 深圳市瑞吉生物科技有限公司 | 一种使目的基因沉默的CasRx制剂及其应用 |
| KR102871759B1 (ko) * | 2022-11-28 | 2025-10-20 | 충북대학교 산학협력단 | 티로시나아제에 특이적으로 결합하는 rna 앱타머 및 이의 용도 |
| CN118388567A (zh) * | 2024-06-26 | 2024-07-26 | 广州表观生物科技有限公司 | 一种特异性靶向酪氨酸酶、制备方法及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2890859B1 (fr) * | 2005-09-21 | 2012-12-21 | Oreal | Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase |
| WO2009039743A1 (fr) * | 2007-09-20 | 2009-04-02 | Suzhou Ribo Life Science Co., Ltd | Arnsi utiles pour l'inhibition de gene tyrosinase, compositions comportant les arnsi et leurs utilisations |
| KR100949791B1 (ko) * | 2007-12-18 | 2010-03-30 | 이동기 | 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도 |
| US20100227920A1 (en) * | 2008-09-29 | 2010-09-09 | The Regents Of The University Of California | Aldehyde dehydrogenase inhibitors as novel depigmenting agents |
| KR101207561B1 (ko) * | 2009-12-15 | 2012-12-04 | 주식회사 코리아나화장품 | 티로시나제의 발현을 저해하는 ｓｉＲＮＡ 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물 |
| ES2930555T3 (es) * | 2010-10-22 | 2022-12-16 | Olix Pharmaceuticals Inc | Moléculas de ácido nucleico que inducen la interferencia de ARN y usos de las mismas |
| CN102719432B (zh) * | 2011-03-29 | 2013-10-23 | 南京大学 | 特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用 |
| JP5720892B2 (ja) * | 2011-07-29 | 2015-05-20 | コニカミノルタ株式会社 | 表示制御装置、操作表示装置、画像処理装置、表示制御方法および表示制御プログラム |
| JP6892433B2 (ja) * | 2015-04-03 | 2021-06-23 | ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | 十分に安定化された非対称ｓｉｒｎａ |
-
2016
- 2016-07-26 JP JP2018504815A patent/JP7027303B2/ja active Active
- 2016-07-26 KR KR1020187004802A patent/KR102772402B1/ko active Active
- 2016-07-26 CA CA3022872A patent/CA3022872C/en active Active
- 2016-07-26 CN CN201680055214.6A patent/CN108138181B/zh active Active
- 2016-07-26 WO PCT/IB2016/001169 patent/WO2017017523A1/en not_active Ceased
- 2016-07-27 US US15/220,767 patent/US10064801B2/en active Active
-
2018
- 2018-08-13 US US16/102,155 patent/US10512600B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526986A5 (enExample) | ||
| JP7235702B2 (ja) | 核酸生成及び送達のための方法及び製品 | |
| JP7027303B2 (ja) | メラニン産生を抑制するｒｎａ複合体 | |
| US11312964B2 (en) | Compositions and methods for modulating growth hormone receptor expression | |
| Uchida et al. | Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002 | |
| JP2023040138A5 (enExample) | ||
| JP2019503199A5 (enExample) | ||
| WO2007056153B1 (en) | Peptide-dicer substrate rna conjugates as delivery vehicles for sirna | |
| WO2008147824A3 (en) | Hydroxymethyl substituted rna oligonucleotides and rna complexes | |
| RU2018112970A (ru) | Конъюгаты олигонуклеотидов | |
| WO2012170957A8 (en) | Retinoid-liposomes for enhancing modulation of hsp47 expression | |
| JP2018533956A5 (enExample) | ||
| WO2012046085A3 (en) | Methods of inducing insulin production | |
| Starlard-Davenport et al. | Targeting genetic modifiers of HBG gene expression in sickle cell disease: the miRNA option | |
| WO2009135165A3 (en) | Small humanin-like peptides | |
| TW201628629A (zh) | 用於生物體內及體外遞送核酸系藥物之新穎糖醇系組成物 | |
| WO2009039743A1 (fr) | Arnsi utiles pour l'inhibition de gene tyrosinase, compositions comportant les arnsi et leurs utilisations | |
| KR20140020820A (ko) | 섬유증 예방 또는 치료제 | |
| JP2016505617A5 (enExample) | ||
| Abubakar et al. | Exploring Novel Therapeutic Breakthroughs for Cancers: Potential Roles of miRNAs | |
| WO2012089207A3 (de) | Pharmazeutische zusammensetzung enthaltend l-dna | |
| KR101841712B1 (ko) | Tslp 발현을 억제하는 올리고뉴클레오타이드 및 이를 포함하는 미용 또는 약제학적 조성물 | |
| JP6324597B1 (ja) | メラニン産生抑制剤、美白剤、遺伝子発現抑制剤、メラニン産生抑制用化粧料組成物及び美白用化粧料組成物 | |
| KR20160016475A (ko) | Tslp 발현을 억제하는 올리고뉴클레오타이드 및 이를 포함하는 미용 또는 약제학적 조성물 | |
| KR102345626B1 (ko) | Rap1a 발현을 저해하는 siRNA 올리고뉴클레오타이드 및 이를 함유하는 멜라닌 생성 억제용 조성물 |